Elanco Receives FDA Approval For Credelio Quattro, The Broadest Canine Oral Parasiticide Protection In A Single Monthly Dose; Launch Expected In Q1 2025
Portfolio Pulse from Benzinga Newsdesk
Elanco Animal Health has received FDA approval for Credelio Quattro, a new canine oral parasiticide offering broad protection against six parasites. The product is set to launch in Q1 2025.
October 07, 2024 | 8:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elanco Animal Health has received FDA approval for Credelio Quattro, a new canine oral parasiticide. This approval could enhance Elanco's product portfolio and market position in the pet health sector.
The FDA approval of Credelio Quattro is a significant milestone for Elanco, as it expands their product offerings in the pet health market. The broad protection against six parasites could make it a preferred choice among pet owners, potentially increasing Elanco's market share and revenues. The launch in Q1 2025 provides a timeline for investors to anticipate potential revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100